Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution

F Francescangeli, ML De Angelis, R Rossi… - Cancer and Metastasis …, 2023 - Springer
The biological complexity of cancer represents a tremendous clinical challenge, resulting in
the frequent failure of current treatment protocols. In the rapidly evolving scenario of a …

Consensus on the RAS dimerization hypothesis: Strong evidence for lipid-mediated clustering but not for G-domain-mediated interactions

DK Simanshu, MR Philips, JF Hancock - Molecular cell, 2023 - cell.com
One of the open questions in RAS biology is the existence of RAS dimers and their role in
RAF dimerization and activation. The idea of RAS dimers arose from the discovery that RAF …

[HTML][HTML] Allostery: allosteric cancer drivers and innovative allosteric drugs

R Nussinov, M Zhang, R Maloney, Y Liu, CJ Tsai… - Journal of molecular …, 2022 - Elsevier
Here, we discuss the principles of allosteric activating mutations, propagation downstream of
the signals that they prompt, and allosteric drugs, with examples from the Ras signaling …

A structural model of a Ras–Raf signalosome

VP Mysore, ZW Zhou, C Ambrogio, L Li… - Nature structural & …, 2021 - nature.com
The protein K-Ras functions as a molecular switch in signaling pathways regulating cell
growth. In the human mitogen-activated protein kinase (MAPK) pathway, which is implicated …

Direct K-Ras inhibitors to treat cancers: progress, new insights, and approaches to treat resistance

R Nussinov, H Jang - Annual Review of Pharmacology and …, 2024 - annualreviews.org
Here we discuss approaches to K-Ras inhibition and drug resistance scenarios. A
breakthrough offered a covalent drug against K-RasG12C. Subsequent innovations …

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

G Yin, J Huang, J Petela, H Jiang, Y Zhang… - Signal transduction and …, 2023 - nature.com
Abstract Small GTPases including Ras, Rho, Rab, Arf, and Ran are omnipresent molecular
switches in regulating key cellular functions. Their dysregulation is a therapeutic target for …

DIRAS3: an imprinted tumor suppressor gene that regulates RAS and PI3K-driven cancer growth, motility, autophagy, and tumor dormancy

G Bildik, X Liang, MN Sutton, RC Bast Jr, Z Lu - Molecular cancer …, 2022 - AACR
DIRAS3 is an imprinted tumor suppressor gene that encodes a 26 kDa GTPase with 60%
amino acid homology to RAS, but with a distinctive 34 amino acid N-terminal extension …

Ovarian cancer: biomarkers and targeted therapy

MR Radu, A Prădatu, F Duică, R Micu, SM Creţoiu… - Biomedicines, 2021 - mdpi.com
Ovarian cancer is one of the most common causes of death in women as survival is highly
dependent on the stage of the disease. Ovarian cancer is typically diagnosed in the late …

Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy

Y Huang, Y Zhen, Y Chen, S Sui, L Zhang - Biochemical Pharmacology, 2023 - Elsevier
Abstract RAS/RAF/MEK/ERK signaling pathway is one of the most important pathways of
Mitogen-activated protein kinases (MAPK), which widely participate in regulating cell …

Conditional Cooperativity in RAS Assembly Pathways on Nanodiscs and Altered GTPase Cycling

SY Lee, KY Lee - Angewandte Chemie, 2024 - Wiley Online Library
Abstract Self‐assemblies (ie, nanoclusters) of the RAS GTPase on the membrane act as
scaffolds that activate downstream RAF kinases and drive MAPK signaling for cell …